Chardan raised the firm’s price target on Immuneering to $13 from $12 and keeps a Buy rating on the shares. The company’s Phase 2a data from 1st line pancreatic cancer patients treated with its lead MEK inhibitor candidate, IMM-1-104, used in combination with modified gemcitabine/nab-paclitaxel, demonstrated clean tolerability for the combo and early signals of activity, the analyst tells investors in a research note. If these results hold as more patients are treated, the ‘104 + mGnP regimen could offer an attractive option for first-line pancreatic cancer patients, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Immuneering announces initial response data from first five IMM-1-104 patients
- Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
- Immuneering price target lowered to $12 from $16 at Chardan
- Immuneering receives fast track designation for IMM-1-104 from FDA
- Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
Questions or Comments about the article? Write to editor@tipranks.com